Touchscreen-based Cognitive Tests in Healthy Volunteers
Brief Summary
This phase Ib study aims to evaluate applicability of touchscreen-based cognitive test battery for assessment of ketamine-induced schizophrenia-like cognitive deficits in healthy volunteers. Additionally, the study aims to assess whether ketamine-induced cognitive deficits are reversed by modafinil using touchscreen-based test battery for testing of cognition.
Intervention / Treatment
-
Drug: Ketamine 0.58
-
Drug: Ketamine 0.31
-
Drug: Modafinil
-
Drug: Placebo for ketamine
-
Drug: Placebo for modafinil
Condition or Disease
- Cognitive Symptom
- Schizophrenia
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Unknown status |
| Study results: | No Results Available |
| Age: | 20 Years to 40 Years (Adult) |
| Enrollment: | 16 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Mar 12, 2018 | |
|---|---|---|
| Primary Completion: | May 16, 2018 | |
| Completion Date: | Dec 31, 2019 | |
| Study First Posted: | Mar 19, 2018 | |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | Oct 16, 2018 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Ketamine-induced schizophrenia-like cognitive deficits in healthy volunteers are measured by using touchscreen-based cognitive tests. In addition, the study aims to assess whether ketamine-induced cognitive deficits detected by touchscreen-based cognitive tests are reversed by modafinil.
Eligibility Criteria
| Sex: | Male |
|---|---|
| Minimum Age: | 20 |
| Maximum Age: | 40 |
More Details
| NCT Number: | NCT03469089 |
|---|---|
| Other IDs: | REVISE28347|2017-004455-22 |
| Study URL: | https://ClinicalTrials.gov/show/NCT03469089 |
Last updated: Jun 17, 2022